Ocata Therapeutics Inc fka OCAT

[elllk]

Some help for evaluating ACTC?

At one point in Maria Bartiromo's interview below Alkermes CEO Richard Pops goes through the valuation of the three corporations represented here, Celgene $30B, Dendreon $6B, and Alkermes $1B and then he says one reason the field is so exciting is:

"You can go from $1B to $6B to $30B on the back of a single drug or two."

Earlier, Dendreon CEO Mitch Gold observed that the latest technology aids companies like Dendreon because smaller companies can now do things that were limited to the largest corporations only 10-15 years ago.

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

CEOs on Business of Biotech

The cost of developing a new drug is higher than ever at a whopping $1.3 billion, according to a new study from Tufts University. Celgene CEO Robert Hugin, Dendreon CEO Mitch Gold and Alkermes CEO Richard Pops tell CNBC what this means for the biotech industry.

http://www.cnbc.com/id/15840232?video=1735380838&play=1